OSE Immunotherapeutics SA (OSE.PA)

5,0000 +0,1250 (+2,56 %) À la clôture : 05:35PM CEST

OSE Immunotherapeutics SA

22, boulevard Benoni Goulin
Nantes 44200
France
33 2 28 29 10 10
https://www.ose-immuno.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Dominique Costantini M.D.	Founder, Chairman of the Board and Director of Development & Strategy	404,11k	S.O.	1956
Dr. Nicolas Poirier Ph.D.	General Director, CEO, Scientific Director & Director	350,15k	S.O.	1982
Ms. Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	S.O.	S.O.	S.O.
Mr. Alexis Peyroles	Consultant	586,59k	S.O.	1974
Dr. Alain Chatelin M.D.	Medical Director	S.O.	S.O.	S.O.
Bérangère Vasseur M.D.	Chief Medical Officer Immuno-Oncology	S.O.	S.O.	S.O.
Mr. Julien Perrier	Chief Commercial Officer	S.O.	S.O.	S.O.
Ms. Linda Lebon M.Sc.	Chief Regulatory Officer	S.O.	S.O.	1967
Dr. Silvia Comis M.D.	Head of Clinical Development	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de OSE Immunotherapeutics SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.